Tag:

New Enterprise Associates

Latest Headlines

Latest Headlines

FierceBiotech Radio with NEA's Carol Gallagher

New Enterprise Associates Partner Carol Gallagher joins FierceBiotech Radio to talk about her journey from Big Pharma to small biotech and eventually to venture capital, along the way shedding light on just what VCs do all day.

NEA raising $2.5B+ life sciences fund

New Enterprise Associates is one of the largest venture investors in the life sciences. And it's one of the few VC firms that also fund medical device companies as part of its broad investment strategy across information technology and healthcare.

Top biotech investor NEA outlines plans for another $2.5B-plus venture fund

In a sign of the times, leading life sciences venture maven David Mott and his colleagues at New Enterprise Associates have begun raising a whopping $2.5 billion venture fund--less than three years after rolling out its latest fund with $2.6 billion.

Abbott creates electrophysiology biz by moving in on a trio of NEA startups

Abbott has made its move on a trio of med tech startups focused on cardiovascular catheterization. It is buying electrophysiology startup Topera for $250 million plus undisclosed milestones and has secured the right to purchase Advanced Cardiac Therapeutics, which has a novel ablation catheter. Plus, Abbott Ventures participated in a venture round for VytronUS.

VC giant NEA recruits biotech vet Carol Gallagher to join its ranks of dealmakers

After more than 25 years in drug development that culminated in a corner office at Calistoga Pharmaceuticals, Carol Gallagher decamped for the venture world last year, and now she has accepted a position at New Enterprise Associates to help nurture the next generation of disruptive biotechs.

NEA pitches in on a $27M gamble on Tracon's mid-stage cancer drug program

New Enterprise Associates has stepped up to back San Diego-based Tracon Pharmaceuticals, joining a syndicate that is betting $27 million on the company's two cancer therapies, including a mid-stage drug now in the clinic for soft tissue sarcoma.

CVRx gets $15M to advance hypertension, heart failure treatment device

On the heels of a $42 million Series F closed last fall, CVRx is picking up an additional $15 million in a debt facility from Silicon Valley Bank. But that's chump change in the long run for this startup, which has raised about $265 million since its 2001 inception.

Intrinsic raising $21M for implant to improve lumbar disc surgery

Intrinsic Therapeutics is aiming at more effective surgical treatment of lumbar disc herniation and is in the process of raising almost $21 million in venture capital, according to a Sept. 17 SEC filing.

Device share of healthcare venture capital funding hits decade low

While medical device venture activity may have picked up this year, the comparison point in 2013 was abysmally low. In addition, Series A device investment was still shrinking. That's according to a new report from Silicon Valley Bank. These trends are pushing the sector to be more reliant on angel investors, which are becoming more accessible with the advent of crowdfunding, and corporate VCs, who are stealthy but increasingly active.

Atlas, NEA bankroll a $30M round for synthetic biology upstart Synlogic

This morning Atlas Venture and New Enterprise Associates announced that they have committed $29.4 million to launch Synlogic, a new Cambridge, MA-based upstart initially seeded last fall that has set out to build a platform that can create therapeutic microbes.